ClinicalTrials.gg
Not yet recruitingNCT07215403PIAUpdated Oct 29, 2026

Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)

A Phase 2 interventional study of Prescriptive Infusion Algorithm and AB-1005 in PARKINSON DISEASE (Disorder), sponsored by AskBio Inc. Not yet recruiting at 4 sites in United States. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by AskBio Inc (part of Bayer) · Phase 2, Interventional, and Treatment

Updated Oct 29, 2026Title changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Parkinson Disease by Bayer — 6 open to participants now, 8 under way, 1 of them phase 3. Parkinson Disease · Bayer.

Started
2026
with 1 other
Phase 2
5 of 12
2 open now
Registered
10th of 12
by date

Among the 12 studies in Parkinson Disease by Bayer, this one is one of 2 that started in 2026, is one of 5 in phase 2, and was the 10th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 12 studies in Parkinson Disease by Bayer are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Parkinson Disease by Bayer, or all of them as a file.
02

Study summary

This study is being done to test a new way of delivering AB-1005 into the brain. The goal is to make the procedure easier and quicker to perform, while providing similar amounts of drug to the part of the brain that needs treatment.

Technical (Stage 0) To test if the new delivery method (prefrontal surgical approach) can consistently deliver AB-1005 to the putamen using MRI monitoring.

Technical (Stage 1) To test if the new delivery method (PIA-based infusion) can consistently deliver AB-1005 to the putamen using brain imaging by MRI.

Technical (Stage 2) To confirm the new delivery method works without brain imaging by MRI, using standard operating room tools including brain imaging by CT.

Safety (Stage 1 and 2) To assess the safety and tolerability of the new delivery method for AB-1005 up to 6 months after surgery

Read the detailed description

Participants will receive a one-time infusion of AB-1005 directly into the putamen on each side of the brain. This is done during a surgical procedure under general anesthesia. The drug is delivered using a special technique called convection-enhanced delivery (CED), which helps spread the drug evenly in the target brain tissue. The delivery method will use either MRI or CT scans to guide and check the placement of the infusion needle (cannula, which is a thin tube).

The study has three main stages, the initial group of 6 participants and the other 2 stages with two small groups (sub-stages) of 3 participants. Each group will receive the same treatment, and results will be reviewed before moving to the next group.

All participants will receive AB-1005. The study is open-label, meaning both participants and doctors know what treatment is given.

After the follow-up period, all participants will continue into a long-term follow-up (LTFU) study. In the LTFU study, participants' health will be monitored for up to 10 years after their surgery.

03

Conditions studied

  • PARKINSON DISEASE (Disorder)

Browse trials for

Keywords

  • PD
  • Parkinsons Disease
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 45 to 75 years of age inclusive, at the time of signing the .
  • >10 years since diagnosis of PD (at time of consenting / Screening Visit 1)
  • Presence of bradykinesia plus any of the following:
  • Rigidity
  • Resting tremor
  • Postural instability
  • Modified Hoehn and Yahr stage III-IV in the practically defined OFF state
  • Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score >40 in the practically defined OFF state
  • Stable anti-PD medication regimen for at least 4 weeks prior to Screening Visit 1 and through Baseline Visit
  • ≥30% reduction in MDS-UPDRS Part III following a levodopa challenge
  • Must agree to use barrier method protection when engaging in intercourse/sexual activity with another person for at least 3 months post-dosing.
  • Male participants must refrain from donating sperm for at least 3 months post-dosing.
  • Female participants cannot be pregnant or breastfeeding at the time of screening. A woman of (WOCBP) must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) at the required assessments
  • Provision of signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
  • Provision of signed consent to also participate in LTFU study ASK-PD0-CS002

Exclusion criteria

Exclusion Criteria:

  • Evidence of secondary or atypical parkinsonism (as determined by the neurologist)
  • Presence or history of psychosis or impulse control disorder (as determined by the neurologist)
  • Presence or history (within 2 years prior to screening) of substance use disorder (including alcohol) as defined by the (DSM-5) criteria (or in the judgment of the neurologist)
  • Presence of untreated or sub optimally treated depression (Beck Depression Inventory [BDI]-II score ≥20)
  • Current suicidal ideation as indicated by positive response to items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C SSRS), or any history of a suicide attempt
  • cognitive impairment ( [MoCA] score \<25)
  • Presence or history of other than treated cutaneous squamous or basal cell carcinomas
  • Presence of clinically active infection, including acute or chronic scalp infection
  • Known to MRI
  • Presence or history of significant cerebrovascular or cardiovascular disease, including:
  • Stroke, , or other suspected cerebrovascular accident within 1 year prior to screening
  • Unstable angina pectoris or myocardial infarction within 1 year prior to screening
  • Revascularization procedure(s) within 1 year prior to screening
  • Poorly controlled hypertension, poorly controlled diabetes mellitus or prediabetes mellitus with known significant microvascular injury, or other significant cardiovascular history or risk factor
  • Known history of complications of anesthesia including difficult airway management and/or difficult endotracheal intubation, malignant hyperthermia, or other related issues that would compromise participant safety during general anesthesia (as determined by the anesthesiologist)
  • Inability to identify a safe trajectory to each putamen via an occipitoparietal entry point, or known contraindications to brain surgery in prone position (as determined by the neurosurgeon)
  • Known allergy or sensitivity to ingredients in the intervention formulation and/or to gadolinium-based contrast agents
  • Concurrent use of percutaneous levodopa/carbidopa intestinal gel, subcutaneous levodopa, or apomorphine pump
  • History of brain surgery (including deep brain stimulation [DBS] or focused ultrasound)
  • Chronic therapy
  • History of prior cell or gene therapy
  • Participation in other interventional clinical trials within 12 weeks prior to screening or unwilling to refrain from starting new agents throughout the course of the study
  • Laboratory values at screening:
  • ≤100,000/mm3
  • PT >15 s, >40 s, and/or INR >1.3
  • (ANC) ≤1500/mm3
  • ≤10.0 g/dL
  • or alanine aminotransferase ≥2.5 times the
  • Total ≥2.5 mg/dL
  • \<45 mL/min/1.73 m2
  • ≥8%
  • Unable to comply with the protocol procedures, including frequent and prolonged follow-up assessments (during LTFU study ASK-PD0-CS002)
  • Unwilling to defer any vaccination from screening through 1 month after surgery
  • Any significant issue raised by the neurologist, neurosurgeon, or anesthesiologist that may make a participant unsuitable for the study
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Stage 1

    Stage 1 is aimed at evaluating the suitability of PIA-based infusion for standardized intraputaminal administration of AB-1005 via CED under iMRI monitoring.

    Procedure: Prescriptive Infusion Algorithm · Drug: AB-1005

Interventions

  • ProcedurePrescriptive Infusion Algorithm

    The study intervention is comprised of the neurosurgical procedure and the bilateral intraputaminal delivery of AB-1005.

  • DrugAB-1005

    bilateral intraputaminal delivery of AB-1005

06

What researchers measure

Primary outcomes

  1. Amount of the putamen covered by the drug at the end of infusion, assessed by MRI

    Investigate the use of PIA-based infusion for consistent intraputaminal administration of AB-1005 via CED under iMRI monitoring

    Time frame: immediately after the intervention/procedure/surgery

Secondary outcomes

  1. Duration of surgical procedure

    Reduce the time the surgical procedure is performed

    Time frame: through study completion, an average of 1 year

  2. Change in total volumetric putaminal coverage within approximately 60-120 min from end of infusion

    Time frame: immediately after the intervention/procedure/surgery

  3. Accuracy of cannula tip placement at targeted first and last infusion stops in putamen

    Time frame: immediately after the intervention/procedure/surgery

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2028, 17 months later.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's planned 17 months is below that.

Counting every sponsor, half of 202 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Oct 10, 2025
StartEst.
Nov 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Nov 1, 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
Prescriptive Infusion Algorithm (PIA)→Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Title Prescriptive Infusion Algorithm (PIA)→Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07215403
Lead sponsor
AskBio Inc
Collaborators
Bayer
Responsible party
Sponsor
First posted
Oct 10, 2025
Start date
Nov 2026 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

AskFirst Patient Engagement
Contact
askfirst@askbio.com
919-561-6210

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion